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Abstract
A novel set of integrated procedures for quantification of fibroblast-rich stroma and vascular characteristics
has recently been presented allowing discovery of novel perivascular and stromal biomarkers in colorectal,
renal cell, and ovarian cancer. In the present study, data obtained through these procedures from clinically
well-annotated collections of these three tumour types have been used to address two novel questions. First,
data have been used to investigate if the three tumour types demonstrate significant differences regarding
features such as vessel diameter, vessel density, and perivascular marker expression. Second, analyses of the
cohorts have been used to explore the prognostic significance of a novel vascular metric, ‘vessel distance
inter-quartile range (IQR)’ that describes intra-case heterogeneity regarding vessel distribution. The compari-
sons between the three tumour types demonstrated a set of significant differences. Vessel density of renal
cell cancer was statistically significantly higher than in colorectal and ovarian cancer. Vessel diameter was
statistically significantly higher in ovarian cancer. Concerning perivascular status, colorectal cancer displayed
significantly higher levels of perivascular PDGFR-b expression than the other two tumour types. Intra-case
heterogeneity of perivascular PDGFR-b expression was also higher in colorectal cancer. Notably, these
fibroblast-dominated stroma phenotypes matched previously described experimental tumour stroma character-
istics, which have been linked to differential sensitivity to anti-VEGF drugs. High ‘vessel distance IQR’ was sig-
nificantly associated with poor survival in both renal cell cancer and colorectal cancer. In renal cell cancer,
this characteristic also acted as an independent prognostic marker according to multivariate analyses including
standard clinico-pathological characteristics. Explorative subset analyses indicated particularly strong prognos-
tic significance of ‘vessel distance IQR’ in T stage 4 of this cancer type. Together, these analyses identified
tumour-type-specific vascular-stroma phenotypes of possible functional significance, and suggest ‘vessel dis-
tance IQR’ as a novel prognostic biomarker.
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Introduction
Tumour vasculature impacts on multiple aspects
of tumour biology [1,2]. The vasculature of solid
tumours affects growth and metastasis propensity.
Interactions between vascular cells and immune cells
also impact on immune surveillance. Furthermore,
vascular properties regulate chemotherapy sensitivity
by affecting drug delivery.
Analyses of properties such as vessel density, vessel
maturation, endothelial cell proliferation, marker
expression, and pericyte status have demonstrated that
these features are associated with prognosis in many
tumour types, such as breast, prostate, ovarian, clear
cell renal cell carcinomas, and glioblastoma [2–6].
Anti-angiogenic treatments targeting VEGF receptor
signaling have been tested in many different tumour
types for treatment of metastatic disease or in adjuvant
settings [7,8]. Results from these clinical studies have
demonstrated tumour-type-specific differences in sensi-
tivity to these drugs when used as mono-treatments.
Well-known examples of tumour-type-specific differen-
ces in efficacy include, for example, the robust effects
of mono-treatment with anti-angiogenic drugs in renal
cell cancer [9], the modest effects in ovarian cancer
[10], and the lack of effects in colorectal cancer [11].
These differences in sensitivity to anti-angiogenic
drugs could reflect systematic functional and structural
differences in the tumour vasculature of different
tumour types. Such differences could be caused by
organ-specific differences in physiological vascular
biology programme. It can also be envisioned that
tumour-type-specific oncogenic drivers are initiating
different angiogenic programmes. Furthermore, results
from studies of metastatic lesions show that different
tumour types use angiogenesis or vessel co-option to
varying degrees, presenting vasculatures with different
degree of maturation [12,13]. Systematic comparisons
of vascular biology features between different tumour
types therefore have the potential to uncover tumour-
type-specific features of vascular biology with mecha-
nistic or therapeutic potential.
Most prognosis studies with vascular markers have
used case-based mean-values of the marker-of-
interest as the basis for scoring of individual tumours.
Recent analyses in ovarian and kidney cancer have
demonstrated that the inside-case heterogeneity
regarding expression of a perivascular marker acts as
a prognostic factor [14]. This suggests the possibility
of prognostic significance also of heterogeneity of
other tumour vasculature characteristics.
This study exploits a set of integrated procedures
for quantification of vascular characteristics, which
recently uncovered novel vascular biomarkers and
suggested novel biological mechanisms in ovarian,
renal cell, and colorectal cancer [5,14,15]. In this
study, data from four tumour collections (colorectal
cancer cohort, colon cancer cohort, ovarian cancer,
and kidney cancer cohorts) have been used to com-
pare vascular characteristics between tumour types.
Furthermore, the previous demonstration of prognos-
tic significance of perivascular heterogeneity has
been extended to analyses of the potential prognostic
significance of ‘vessel distance IQR’; a ‘metric’ cap-
turing intra-case heterogeneity regarding inter-vessel
distances [14].
Material and methods
Tumour cohorts and tissue micro-arrays
Details about the tumour cohorts have been described
previously [5,14,16]. In brief, the ovarian cancer col-
lection (OC) is composed of 109 cases of primary
adnexal site tissues deriving from patients affected
by serous ovarian cancer collected consecutively
between 1985 and 2006 at the University Medical
center Groningen (Groningen, The Netherlands) [17].
The renal cell cancer collection (RCC) is composed
of 288 primary tumours from surgically treated
patients diagnosed at Malmo University Hospital
(current Ska˚ne University Hospital), between 1978
and 1996 [14]. The colorectal cancer collection
(CRC) is composed of primary tumours from 447
patients diagnosed in Malmo University Hospital.
This cohort originates from the population-based pro-
spective study, the Malmo Diet and Cancer Cohort,
that enrolled individuals between 1991 and 1996
[16]. The colon cancer cohort was made up of pri-
mary tissues derived from 93 patients from a Nordic
randomized clinical trial performed to evaluate
the efficacy of 5-FU (5-fluorouracil)-based adjuvant
chemotherapy [18]. The original study included 2224
patients younger than 76 years with stages II-III colon
cancer radically resected in 1991 – 1997. The present
study is based on a selection from the original study
of Swedish cases of colon cancer. No patient received
radiotherapy or chemotherapy prior to surgery.
All tissues were collected prior to chemotherapy
treatment. Preparation of tissue micro-arrays fol-
lowed standard procedures and is described in previ-
ous publications [5,14,16,17]. In the different
TMAs, each case is represented by two (colorectal
and kidney) or up to four (ovarian cancer) ‘tissue
punches’. TMA preparation was approved by appro-
priate ethical committees.
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Ethical approvals have been obtained (Dnr 530/
2008 for the colorectal collection, Malmo Diet and
Cancer Cohort; Dnr 00–260, 2014/664–32 for the
Mammoth CRC-cohort, Dnr 282/2007 for the renal
cell cancer collection Ska˚ne University Hospital; Dnr
2016/551–32 for the ovarian cancer collection, origi-
nal certification can be provided by Dr G. Bea A.
Wisman).
Immunohistochemistry and slide scanning
Procedures for double staining with PDGFR-b/a-
SMA and CD34 antibodies have been described ear-
lier together with details of the a-SMA detection
antibody [5,14,15]. The antibody used for PDGFR-b
detection was 28E1 Rabbit mAb, 3169, Cell Signal-
ing Technology. CD34 stains were performed with
the antibody clone QBEnd 10, M7165 Mouse mAb,
DAKO [5,14,15]. Detection of primary antibodies
followed standard procedures as described previously.
Stained slides were subsequently scanned using a
Vslide scanning microscope (Metasystems, Alltlus-
sheim, Germany).
Specificity of the PDGF-b-receptor antibody has
been extensively characterized in earlier studies, includ-
ing test-staining of sections of paraformaldehyde-fixed
paraffin-embedded cultured cells of known PDGF
receptor status [19].
Images analyses
Images were analyzed with ImageJ software using an
algorithm developed in-house [14,15]. Subsequent
data analysis was performed with R (R 3.2.2 GUI
1.66 Mavericks build (6996) http://www.R-project.
org).
CD34 staining was used to determine vessel den-
sity, vessel diameter, and vessel distance to the near-
est vessel. a-SMA- and PDGFR-b-staining were used
as markers for cancer-associated fibroblasts and peri-
vascular cells.
Perivascular area was defined as the region cir-
cumjacent to, and extending 5.5 mm away from, the
vessel. The intensity of perivascular marker expres-
sion (a-SMA or PDGFR-b) was measured in each
such area. A case-based value was obtained (perivas-
cular intensity (PVI) by calculating the median inten-
sity for all perivascular areas of each case (see
Fr€odin et al for more details [14]).
Marker-positive stroma fraction was defined as the
fraction of the analyzed sample, excluding perivascu-
lar regions (see above) and vessel regions, that dis-
played an expression level above a threshold level.
(see Frodin et al for more details [14]).
For scoring of PDGFR-b intensity, we used a
tumour-type-specific scale to accommodate potential
systematic differences between the cohorts regarding,
for example, tissue quality and antigen preservation.
The intensity was determined within each tumour
type using a scale ranging from 0 to 1 with 0 as the
lowest noted intensity and 1 as the highest detected
intensity. This enabled comparison between tumour
types regarding how cases were distributed within
each tumour-specific scale.
A set of procedures was used to obtain a value for
each case that would be related to vessel density
heterogeneity. First, distance to closest vessel was
determined for all vessels of all cases. Second, a
median-based value for vessel-distance was deter-
mined for each case. Third, to quantitate the intra-
case heterogeneity of vessel distribution, the differ-
ence between first and third quartiles were calculated
for each case. This metric was designated ‘vessel dis-
tance IQR’.
Data processing
For comparison between tumour types for marker-
intensity-related metrics, the original data for each
tumour type was normalized and given values
between 0 and 1. Normalization was performed case-
wise for fibroblast-dominated stroma intensity and
vessel-wise for perivascular status. Normalization
addressed the issue of skewed distribution of data by
skewness adjustment as described by Vanderviere
[20] and ‘vessel distance IQR’ metrics were dicho-
tomized per the median.
Statistical analyses
All tests were carried out at the 95% statistical sig-
nificance level and were performed using SPSS ver-
sions 22 and 23 (SPSS Inc., Chicago, IL) and
Rstudio (Version 0.99.489 – VC 2009–2015 RStudio,
Inc.)
Differences between tumour types regarding case-
based values for fibroblast-dominated stroma metrics,
as analyzed in in Figure 1, were determined using
the Mann-Whitney U test. Correlations between case-
based stroma metrics, as analyzed in Figure 2, were
determined using the Spearman correlation test
for pair-wise analyses. Log Rank Tests and Cox
Regression Models were used to estimate relation-
ships between analyzed metrics and overall survival
(Figure 4, Table 1, and supplementary material,
Table S3). Associations with the clinico-pathological
characteristics were evaluated with Pearson’s Chi
Square test (supplementary material, Table S2a–c).
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Figure 1. Comparisons of CRC, RCC, and OC regarding case-based values for vascular and stroma features. Box plots comparing CRC,
RCC, and OC tumours with regard to case-based values for stroma features. The tumour stroma features analyzed are (A) mean inten-
sity of stromal PDGFR-b-expression; (B) abundance of PDGFR-b-positive tumour stroma; (C) vessel density; (D) mean vessel size;
(E) vessel size heterogeneity; (F) heterogeneity regarding inter-vessel distances, ‘vessel distance IQR’; (G) mean intensity of perivascu-
lar PDGFR-b-expression; and (H) heterogeneity regarding perivascular PDGFR-b-expression. For procedures used to obtained case-
based values for these stroma features, see Material and Methods section.
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Results
Comparison between tumour types with regard to
fibroblast-dominated stroma and vascular features
The main analyses were performed on four different
population-based collections of primary tumours,
which have been used in earlier biomarker studies
(see Material and Methods and supplementary mate-
rial, Table S1a–c for cohort descriptions, [5,14]). Ini-
tial analyses focused on comparing different vascular
and fibroblast-dominated stroma features between
colorectal cancer (CRC), renal cell cancer (RCC) and
ovarian cancer (OC; Figure 1A–D,G). Data were also
used to compare intra-case heterogeneity of vascular
and perivascular features (Figure 1E,F,H; see
Materials and Methods and [14] for details concern-
ing the metrics ‘vessel size IQR’ and ‘perivascular
intensity [PVI] IQR’).
Fibroblast-rich stroma
RCC displayed the statistically significantly highest
expression levels of PDGFR-b in the tumour stroma
(Figure 1A). The fraction of tumour area positive for
the fibroblast marker PDGFR-b was highest in CRC
(Figure 1B). Examples of cases with significantly
high and low PDGFR-b stroma fraction, from each
of the three tumour types, are shown in supplemen-
tary material, Figure S1. Independent analyses using
a-smooth muscle actin as a fibroblast marker yielded
similar results when tumour types were analyzed with
Figure 2. Comparisons of CRC, RCC, and OC regarding correlations between different stroma features. (A) Panels illustrate pair-wise
correlation analyses of case-based values for stroma features in CRC (upper), RCC (middle), and OC (lower). The left part contains
analyses of the correlations between vascular features (vessel density, vessel diameter, and mean intensity of perivascular PDGFR-b-
expression [PDGFR-b PVI]) and abundance of PDGFR-b-positive tumour stroma (PDGFR-b-positive stroma fraction). The right part
contains analyses of the correlations between the three different vascular features. For procedures used to obtained case-based val-
ues for these stroma features, see Material and Methods section. (B) The graph illustrates the relationship between vessel diameter
and perivascular PDGFR-b-intensity in vessels of CRC, RCC, and OC using vessel-based values. For details concerning methods to
obtain data for perivascular PDGFR-b-status and diameter of individual vessels, see Material and Methods.
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regard to abundance of fibroblast-rich stroma (supple-
mentary material, Figure S2a).
Vessels
RCC cases displayed statistically significantly higher
vessel density as compared to OC and CRC (Figure
1C). Concerning vessel size, analyses showed that
both absolute values and intra-case variation of vessel
size were larger in OC in comparison to CRC and
RCC (Figure 1D,E).
Perivascular cells
CRC cases showed significantly higher absolute values
and intra-case variation of perivascular PDGFR-b
expression (Figure 1G,H). Examples of cases with high
and low PDGFR-b perivascular intensity, from each of
the three tumour types, are shown in supplementary
material, Figure S3. Independent analyses using a-SMA
as a marker for perivascular cells demonstrated that the
tumour-type-related differences were not detected when
this marker was used for perivascular cells (supplemen-
tary material, Figure S2b).
Associations between stroma and vascular metrics
in each of the analyzed tumour types
Case-based values for vessel density, vessel size,
and perivascular status were compared with regard
to pair-wise correlation within the different tumour
types (Figure 2A, right part). Associations between
vessel densities, vessel size and perivascular status
were in general low, as described in our previous
publications. However, in RCC, but not in CRC and
OC, cases with higher vessel density were also
characterized by lower perivascular status, resulting
in moderate negative correlation (Spearman
r520.43) between these two metrics (Figure 2A,
right part).
Vessel characteristics were also compared to
PDGFR-b status in tumour fibroblast-dominated stroma
(Figure 2A, left part). These metrics showed strong pos-
itive correlations (Spearman r5 0.71, 0.67 and 0.83,
respectively).
For additional analyses of potential relationships
between vessel size and perivascular status, data
were analysed in a vessel-based, rather than case-
based manner. As shown in Figure 2B, these analyses
confirmed the previous case-based findings of the
absence of strong correlation between vessel size and
perivascular status in OC and RCC. In contrast, ves-
sels in CRC displayed a more complicated pattern:
perivascular expression of PDGFR-b is highest in
vessels of 5–15 mm diameter. For vessels bigger than
15 mm the intensity of the perivascular expression of
PDGFR-b appeared inversely correlated with vessel
size.
Table 1. Uni- and multivariate Cox regression analyses of survival association of ‘vessel distance IQR’ and clinical characteristics in RCC
Variables
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age at diagnosis
<50 1 (reference) 0.01 1 (reference) 0.03
>50 2.11(1.17–3.81) 2.94 (1.08–8.00)
Gender
Female 0 1 (reference) 0.80 1 (reference) 0.82
Male 1 1.04 (0.76–1.42) 0.93 (0.50–1.72)
T stage
1 1 (reference) 0.11 1 (reference) 0.36
2 2.56 (0.82–8.06) 0.035 2.15 (0.43–10.82) 0.05
3 3.38 (1.09–10.48) < 0.001 4.63 (0.99–21.74) 0.003
4 12.1 (4.31–33.99) 9.87 (2.16–45.20)
M stage
0 1 (reference) <0.001 1 (reference) 0.002
1 6.22 (4.29–9.02) 3.6 (1.60–8.10)
Fuhrman grade
1 1 (reference) 0.53 1 (reference) 0.76
2 1.13 (0.71–1.51) <0.001 1.14 (0.48–2.69) 0.21
3 2.49 (1.57–3.50) <0.001 1.76 (0.72–4.26) 0.12
4 8.6 (5.12–14.84) 2.61 (0.78–8.80)
Histology
Non-clear cell 1 (reference) 0.73 1 (reference) 0.53
Clear cell 1.14 (0.56–2.33) 1.44 (0.47–4.47)
IQR vessel distances
Low 1 (reference) <0.001 1 (reference) 0.006
High 1.95 (1.42–2.68) 2.46 (1.29–4.69)
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High heterogeneity in vessel-distribution is
associated with poor survival in RCC and CRC
Previous analyses of the OC and RCC cohort have
demonstrated that high heterogeneity of the perivas-
cular status is associated with poor prognosis [5,14].
In the present study, we introduced a novel metric
denoted ‘vessel distance IQR’, which describes the
variation in distance to the closest located vessel for
each vessel in a tumour sample. This novel metric
was investigated regarding its association with other
clinico-pathological characteristics and with survival.
Image examples of cores from the OC, RCC, and
CRC cohorts with high and low ‘vessel distance
IQR’ are shown in Figure 3.
The associations of ‘vessel distance IQR’ with
standard clinico-pathological characteristics are shown
in supplementary material, Table S2a–c. In the CRC
cohort, high heterogeneity of vessel density correlated
significantly with female sex, advanced T- and M-
stage and low differentiation grade (supplementary
material, Table S2a). In RCC, high heterogeneity of
vessel density was significantly associated with male
sex and high Fuhrman grade (supplementary material,
Table S2b). No significant association was found in
the OC cohort between ‘vessel distance IQR’ or any
of the clinico-pathological characteristics (supplemen-
tary material, Table S2c).
Notably, as shown in the Kaplan-Meier plots of Fig-
ure 4, high heterogeneity in vessel density was signifi-
cantly associated with poor survival in both RCC and
CRC (median survival 95 months versus 36 month,
HR5 1.95 (Confidence Intervals at 95% CI95%:
1.42–2.68), p< 0.001 and median survival 10.31 years
versus 6.24 years, HR5 1.29 (CI95%: 1.00–1.67),
p5 0.05, for RCC and CRC, respectively). Heteroge-
neity in vessel density in OC had no impact on sur-
vival (HR5 1.04 [Cl95%: 0.66–1.64], p5 0.86).
In RCC and CRC, additional analyses tested the
independence of vessel distance IQR from standard
clinico-pathological characteristics, by Cox uni- and
multi-variate analysis. As shown in Table 1, this
novel metric acted as an independent marker of prog-
nosis in RCC (HR5 2.46 [CI95%: 1.29–4.69],
p5 0.006), but not in CRC (supplementary material,
Table S3).
Explorative analyses were performed to investigate
if vessel density heterogeneity showed differential
prognostic significance in various subsets of RCC
and CRC (supplementary material, Figure S4a,b). In
RCC, the strongest association between high heteroge-
neity of vessel density and short survival was seen in
the T stage IV and in clear cell histology (supplemen-
tary material, Figure S4a). The analyses of CRC indi-
cated that the survival association of heterogeneity of
Figure 3. CRC, RCC, and OC cases with high or low inter-vessel distance heterogeneity (vessel distance IQR). Photomicrographs
showing examples of CRC (left), RCC (middle), and OC (right) tumours with high (upper) or low (lower) heterogeneity regarding inter-
vessel distances. Sections have been stained to detect endothelial cells with CD34 antibodies (red) and with PDGFR-b antibodies
(blue).
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vessel density was stronger in males as compared to
females (supplementary material, Figure S4b).
Discussion
Through analyses of a large dataset, obtained from
state-of-the-art multi-parametric stroma-profiling of
three clinically well-annotated tumour collections,
this study identifies different stroma phenotypes in
three common types of cancers.
The major findings from the comparative analyses
are summarized in Table 2. The defining properties
of RCC include a high vessel density together
with low abundance of PDGFR-b-positive tumour
fibroblast-dominated stroma. Vessels of RCC are in
general small and display low perivascular PDGFR-b
expression. CRC is characterized by low vessel
density, high abundance of PDGFR-b-positive fibro-
blast-dominated stroma, and high perivascular
PDGFR-b-positivity. OC presents a third phenotype
including low vessel density, larger vessel size, low
perivascular PDGFR-b expression, and moderate
amounts of PDGFR-b-positive fibroblast-dominated
stroma. Notably, the tumour-type-specific differences
regarding perivascular status were not detected in
analyses using alpha-smooth-muscle actin as a
perivascular marker, confirming findings that these
markers detect different subsets of perivascular cells
[5,14,21].
The tumour-type-specific vessel properties indicate
reliance on different angiogenic programmes. The
high vessel density/low perivascular coverage pheno-
type of RCC is compatible with VEGF-driven angio-
genesis not balanced by a vessel-maturation
programme including recruitment of PDGFR-b-
positive perivascular cells [22,23]. RCC furthermore
displays an inverse relationship between vessel den-
sity and perivascular status – a feature not observed
in CRC or OC (Figure 2). This phenotype is possibly
linked to the well-established “VEGF-high” charac-
teristics of RCC, which occur as a consequence of
VHL-deficiency, and activation of HIF [24]. In con-
trast, the vasculature of CRC has features of higher
maturation and might thus reflect a strong involve-
ment of physiological vascular programmes of the
sub-epithelial mucosa. This is compatible with the
growth pattern of CRC, which involves invasion into
the mucosa, which is composed of vascularized loose
connective tissue.
Interestingly, the phenotypes emerging from these
analyses correspond well to earlier described ‘fibroblast-
dominated stroma phenotypes’ which have been linked
to the sensitivity to anti-angiogenic therapy [25]. The
study of Smith et al, predominantly relying on analyses
of different experimental tumour models, identified a
‘tumour vessel’ phenotype and ‘fibroblast-dominated
stroma vessel phenotype’ largely overlapping with the
RCC-OCand CRC phenotypes, respectively, of the
present study. Notably, the ‘tumour vessel’/RCC-OC
phenotype displayed a greater sensitivity to treatment
with anti-VEGF agent, in agreement with the clinical
experience of efficiency of treatment with such drugs in
Figure 4. Associations between heterogeneity of inter-vessel-distances and overall survival in CRC, RCC, and OC. Kaplan-Meier curves
for overall survival, with P values of Log Rank test, in CRC, RCC, and OC for cases defined by vessel distance IQR.
Table 2. Summary of stroma features in RCC, CRC, and OC
Metric RCC CRC OC
Vessel density High Low Low
Vessel size Low Low High
PDGFR-b PVI Low High Low
Stroma abundance Low High Low
PDGFR-b PVI/stroma correlation High High High
Vessel density/PDGFR-b PVI correlation High Low Low
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RCC [26] and in maintenance therapy of OC [10,27],
but not in CRC [11,28]. An implication of these find-
ings, for possible future testing, is that ‘outliers’ of CRC
with an RCC-like tumour stroma might be sensitive to
anti-VEGF treatments. Furthermore, it could be tested
whether the anti-VEGF-benefit in OC is particularly
strong in cases displaying the most typical ‘perivascular-
low’ phenotype.
A series of recent studies have indicated that
tumour metastasis relying on vessel co-option dis-
plays a reduced sensitivity to anti-VEGF-agents
[13,29–31]. Among the primary-tumour-derived vas-
cular phenotypes of the present study, the CRC-type
vessels with high PDGFR-b expression are most sim-
ilar to the VEGF-antagonist-resistant co-opted metas-
tasis vessels. Future studies should also explore the
presence of the CRC primary tumour vessel pheno-
type in metastatic lesions, and describe its sensitivity
to VEGF-antagonists.
Concerning mechanisms for ‘fibroblast-dominated
stroma-building’ a strong intra-case correlation of
PDGFR-b expression in fibroblast-stroma and peri-
vascular regions was noted (Figure 2, left panel).
This indicates that related cells populate these
compartments. This notion is supported by recent
lineage-tracing studies which have established strong
links between perivascular cells and fibroblasts/myo-
fibroblasts in different settings [30,32–34].
This study identified previously un-recognized
prognostic significance in RCC of a novel metric,
‘vessel distance IQR’, related to the distribution of
vessels (Figure 4 and Table 1). It is recognized that
this finding should be validated in independent RCC
cohorts. It is noted as a limitation of the present
study that analyses have been performed on cohorts
with some samples dating back to the 1980s. Since
then, new treatment strategies have been imple-
mented such as bevacizumab and PARP-inhibitors in
OC, and tyrosine kinase inhibitors (TKIs) and check
point inhibitors in RCC. Future studies on other
cohorts should address potential response-predictive
significance of ‘vessel distance IQR’. Such studies, if
relying mostly on analyses of primary tumours for
biomarkers predicting sensitivity of metastatic lesions
to drug-of-interest, should also integrate analyses of
the ‘stability’ of vascular and fibroblast features in
matched primary tumours and metastatic lesions.
The finding of prognostic significance of ‘vessel
distance IQR’ illustrates the potential of digital
image-analyses-based scoring of vascular features for
the development of features or ‘metrics’ that cannot
be scored or detected with conventional visual
inspection of stained tumour sections. It can be envi-
sioned that continued analyses of the existing data-
set will allow generation of additional ‘higher-level’
features of mechanistic relevance as well as bio-
marker significance. Such studies should also explore
to what extent variations in tumour microenviron-
ment composition can be explained by different
changes in the cancer genome.
For future studies, it is noted that the profiling
of the present study can be extended to additional
features, such as vascular proliferation or marker-
defined subsets of perivascular and endothelial cells.
Such studies, together with the collective findings of
the present work, should contribute to the long-term
goal of exploiting tumour stroma variability for clini-
cally meaningful tumour sub-typing and patient
stratification.
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